Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Effect of rofecoxib therapy on measures of health-related quality of life in patients with osteoarthritis
Autore:
Ehrich, EW; Bolognese, JA; Watson, DJ; Kong, SX;
Indirizzi:
Merek & Co Inc, Outcomes Res, Whitehouse Stn, NJ 08889 USA Merek & Co IncWhitehouse Stn NJ USA 08889 , Whitehouse Stn, NJ 08889 USA Merck Res Labs, Pulm Immun Clin Res & Clin Biostat, Rahway, NJ USA Merck Res Labs Rahway NJ USA mun Clin Res & Clin Biostat, Rahway, NJ USA Merck Res Labs, Clin Biostat, Blue Bell, PA USA Merck Res Labs Blue Bell PA USA es Labs, Clin Biostat, Blue Bell, PA USA
Titolo Testata:
AMERICAN JOURNAL OF MANAGED CARE
fascicolo: 6, volume: 7, anno: 2001,
pagine: 609 - 616
SICI:
1088-0224(200106)7:6<609:EORTOM>2.0.ZU;2-E
Fonte:
ISI
Lingua:
ENG
Soggetto:
RHEUMATOID-ARTHRITIS; OSTEO-ARTHRITIS; SURVEY SF-36; KNEE; CYCLOOXYGENASE-2; INHIBITOR; HIP;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Social & Behavioral Sciences
Clinical Medicine
Citazioni:
18
Recensione:
Indirizzi per estratti:
Indirizzo: Kong, SX Merek & Co Inc, Outcomes Res, 1 Merck Dr WS1B-75, Whitehouse Stn,NJ 08889USA Merek & Co Inc 1 Merck Dr WS1B-75 Whitehouse Stn NJ USA 08889 USA
Citazione:
E.W. Ehrich et al., "Effect of rofecoxib therapy on measures of health-related quality of life in patients with osteoarthritis", AM J M CARE, 7(6), 2001, pp. 609-616

Abstract

Background: Bodily pain and physical disability can negatively impact health-related quality of life (HRQL) in patients with osteoarthritis (OA). Objective: To assess the effects of treatment with a new agent, rofecoxib,on HRQL in patients with OA. Study Design: Randomized, double-blind, 6-week clinical trial comparing treatment with rofecoxib, 5 to 50 mg, with placebo in 672 patients with OA ofthe hip or knee. Main Outcome Measure: Patient HRQL was assessed at baseline and at the endof treatment using the Medical Outcomes'Study 36-Item Short-Form Health Survey (SF-36). Results: At 6 weeks, mean change from baseline in all SF36 mental and physical health domain scores demonstrated significant improvement with rofecoxib use (P < .05 for all doses for all SF-36 domains), with evidence of a dose-response relation. Improvements in mental and physical HRQL domains withrofecoxib treatment were significantly greater than those with placebo treatment (P < .05 for each dose of rofecoxib vs placebo for all domains except general health) and highly correlated with improvements observed using disease-specific OA outcome measures such as the Western Ontario and McMasterUniversities Osteoarthritis Index-visual Analog 3.0 OA index pain and physical function subscales. The effect of rofecoxib vs placebo treatment on mental health largely disappeared after adjustment for improvement in OA disease-specific measures. Conclusions: Rofecoxib treatment increased physical and mental HRQL domainscores on the SF-36. Improvements in mental health with rofecoxib use primarily resulted from effective treatment of OA (ie, reduction in pain and improvement in physical function).

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 28/03/20 alle ore 22:43:10